Electrochemotherapy on Head and Neck Cancer

• Status: Unknown status
• Trial end date: 2019-09-01
• Target enrollment: 0
• Participant gender: All

Summary

A phase II clinical trial testing electrochemotherapy on mucosal recurrent head and neck cancer. Twenty-five patients will be treated. Primary outcome is tumour response on imaging. Secondary outcomes are response from tissue samples, VAS score, Quality of life evaluation and side effects to treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rigshospitalet, Denmark
• Collaborator: Copenhagen University Hospital at Herlev
• Treatments: Bleomycin

Criteria

Inclusion Criteria:

1. Subject age > 18 years.

2. Verified cancer of the head and neck area of any histology.

3. At least one tumour lesion should be accessible for electroporation.

4. Performance status WHO <= 2nd

5. Progressive and / or metastatic disease.

6. Expected survival of > 3 months.

7. Measurable disease is defined as at least one measurable lesion by RECIST 1.1.

8. A treatment-free interval of more than 4 weeks since chemotherapy or radiation therapy.

9. The participant should have been offered the current standard treatment. If there are no further standard treatment to offer or if the participant does not want to receive this, the participant may be included in the trial.

10. The participant should be able to understand the information for participants and be willing and able to comply with hospitalization in the treatment and the agreed follow-up visits and tests.

11. Platelets ≥ 50 billion / L, INR (international normalized ratio) > 1.5. Medical correction is permitted, e.g. correction using vitamin K.

12. Sexually active women who can become pregnant should use adequate contraception during this trial and 6 months after administration of bleomycin (pill, spiral, injection of prolonged progestin subdermal implantation, hormone-containing vaginal devices, transdermal patches).

13. Signed informed consent. -

Exclusion Criteria:

Participants should be excluded if they meet just one of the criteria stated below.

1. Symptomatic progression of the participants cancerous disease that requires another intervention.

2. Acute lung infection

3. Symptoms of lung function impairment. This triggers a lung function test (DLCO = diffusing capacity of the lungs for carbon monoxide), if moderate to severe the participant will be excluded.

4. Previous bleomycin treatment with cumulative dose more than 240,000 Units / m2.

5. History of severe allergic reactions associated with bleomycin.

6. Allergy to constituents of the planned anesthetic.

7. Coagulation disorder which can not be corrected.

8. Chronic renal dysfunction with creatinine> 150 micromoles / liter, will trigger a Cr-51-EDTA (Chromium-51-ethylenediamine tetra acetic acid) clearance. If this is too impaired, the participant is excluded.

9. Pregnancy or lactation.

10. While participation in other clinical trials involving experimental drugs or involved in a trial within 4 weeks prior to study drug administration.

11. Other disorders investigator finds incompatible with participation in the trial. -